An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Naïve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasabuvir and Ribavirin (RBV) for 12 Weeks

Trial Profile

An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Naïve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasabuvir and Ribavirin (RBV) for 12 Weeks

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacodynamics; Registrational
  • Sponsors AbbVie
  • Most Recent Events

    • 05 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Feb 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top